Gene Therapy Improves Vision in hereditary blindness: Study Finds
Bothnia dystrophy is a form of hereditary blindness that leads to progressive visual impairment due to the destruction of the visual cells in the retina. A new study at Karolinska Institutet published in Nature Communications shows that gene therapy can improve vision in patients with the disease.
The disease is caused by an inherited genetic mutation that leads to damage to a particular protein in the eye. There is currently no treatment for the disease.
Researchers at the Karolinska Institute have now investigated whether gene therapy can improve vision in people with the disease.
The researchers used a so-called viral vector, a specially designed virus that was genetically modified to contain a functioning RLBP1 gene, the gene that is damaged in Bothnia dystrophy.
The viral vector was injected under the retina through an advanced surgical procedure in 12 people with the disease. The aim is that after treatment, the viral vector will be taken up by the cells of the retina, where it can produce normal protein.
The preliminary results of the study show that the visual function of 11 of the subjects improved significantly.
"The results are important because hereditary blindness is the most common cause of blindness in younger and able-bodied people, and there is no treatment for the vast majority of those affected," says Helder André, one of the researchers behind the study, who works at the Department of Clinical Neuroscience, Karolinska Institutet.
After the procedure, the researchers followed the study subjects for a year to study the safety and effect of the drug on visual function.
In eleven of the twelve study subjects, night vision, among other things, improved significantly, and in several participants, this led to improved self-perceived quality of life.
No serious side effects linked to the drug were noted in the study.
"Our study gives hope that this large group of patients can have their vision restored in the future. The results also support the idea that gene therapy can work for hereditary diseases in general," says Anders Kvanta, professor of ophthalmology at the same department and the person who led the study.
Reference: Anders Kvanta, Nalini Rangaswamy, Karen Holopigian, Christine Watters, Nicki Jennings, Melissa S. H. Liew, Chad Bigelow, Cynthia Grosskreutz, Marie Burstedt, Abinaya Venkataraman, Sofie Westman, Asbjörg Geirsdottir, Kalliopi Stasi, Helder André. Interim safety and efficacy of gene therapy for RLBP1-associated retinal dystrophy: a phase 1/2 trial. Nature Communications, 2024; 15 (1) DOI: 10.1038/s41467-024-51575-4
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.